Human Cytomegalovirus Envelope Glycoprotein B (gB) Drugs Development Research Report 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Human Cytomegalovirus Envelope Glycoprotein B (gB) pipeline Target constitutes close to 10 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 1 respectively.

Report covers products from therapy areas Infectious Disease, Oncology and Women's Health which include indications Cytomegalovirus (HHV-5) Infections, Chlamydia Infections, Ebolavirus Infections (Ebola Hemorrhagic Fever), Female Contraception, Gonorrhea, Human Immunodeficiency Virus (HIV) Infections (AIDS), Medulloblastoma, Recurrent Glioblastoma Multiforme (GBM), Simplexvirus (HSV) Infections and Trichomonas Vaginitis.

The latest report Human Cytomegalovirus Envelope Glycoprotein B - Drugs In Development, 2021, outlays comprehensive information on the Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

• The report provides a snapshot of the global therapeutic landscape for Human Cytomegalovirus Envelope Glycoprotein B (gB)
• The report reviews Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics and enlists all their major and minor projects
• The report assesses Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Human Cytomegalovirus Envelope Glycoprotein B (gB) targeted therapeutics

Key Topics Covered:

Introduction

• Report Coverage

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Overview

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Development

• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Therapeutics Assessment

• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Companies Involved in Therapeutics Development

• AlphaVax Inc
• Citranvi Biosciences LLC
• Helocyte Biosciences Inc
• Merck & Co Inc
• Stadius Biopharma LLC
• Trellis Bioscience Inc
• VBI Vaccines Inc
• Yaso Therapeutics Inc

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Drug Profiles

AVX-601 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Bi-specific Monoclonal Antibody to Target CD3 and Glycoprotein B for Cytomegalovirus (HHV-5) Infections - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Cytomegalovirus vaccine - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

cytomegalovirus vaccine - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

cytomegalovirus vaccine 1 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Monoclonal Antibodies to Inhibit gH and gB for Cytomegalovirus Infections - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

PPCM - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

TRL-345 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

VBI-1501 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

VBI-1901 - Drug Profile

• Product Description
• Mechanism Of Action
• R&D Progress

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Dormant Products

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Discontinued Products

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Product Development Milestones

Featured News & Press Releases

• Jun 08, 2021: VBI Vaccines granted FDA fast track designation for VBI-1901 for the treatment of recurrent GBM
• May 20, 2021: VBI Vaccines to present updated phase 2a tumor response and overall survival data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting
• Nov 19, 2020: VBI Vaccines announces positive interim Phase 2a data from VBI-1901 in recurrent GBM
• Nov 09, 2020: VBI Vaccines announces e-poster presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting
• Sep 17, 2020: VBI Vaccines announces biomarker data from VBI-1901 phase 1/2a study in recurrent GBM presented at ESMO Virtual Congress 2020
• Sep 14, 2020: VBI Vaccines to present additional biomarker data from VBI-1901 phase 1/2a study in recurrent GBM in an E-Poster at ESMO Virtual Congress 2020
• Jun 22, 2020: VBI Vaccines announces data from VBI-1901 presented at AACR 2020: Partial response observed, promising biomarker strategy identified
• May 15, 2020: VBI Vaccines announces upcoming poster presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting
• Mar 03, 2020: VBI Vaccines doses first recurrent GBM patient in trial of VBI-1901
• Mar 03, 2020: VBI Vaccines provides update on part A of ongoing Phase 1/2a study demonstrating overall survival benefit for VBI-1901 vaccine responders in recurrent GBM patients

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x8i3ff